Bellevue Healthcare Trust: What's going on with the FDA?

Paul Major, fund manager on Bellevue Healthcare Trust (BBH), discusses the current state of the FDA and its impact on the pharmaceutical industry. He highlights the challenges investors face in understanding the FDA's operations, the implications of staff turnover, and the competition from Chinese companies. Major emphasises the need for reforms in drug approval processes to enhance the competitiveness of the US pharmaceutical sector and the importance of innovation in developing new medicines.